Paper Review Records
全部论文审稿周期
21 篇有效样本 · 按发表日期由新到旧排列
审稿天数=录用日期-收稿日期;保留 PDF/DOI/网页源链接
119
天
133
天
Leveraging Regulatory Reliance to Streamline Management of CMC Post-Approval Changes: Industry insights from Multi-Country Reliance Pilots
作者
Mónica Perea-Vélez; Marie Kirman; Anjana Patel; Mark Pellett; Mandy Tyler-Mahon; Thomas F. Perrone; Cynthia Ban; Susanne Ausborn; Frank Montgomery展开收起
作者单位
1. GlaxoSmithKline, Wavre, Belgium; 2. AstraZeneca, Macclesfield, Cheshire, UK; 3. Pfizer Ltd, Surrey, UK; 4. AstraZeneca, Cambridge, UK; 5. GlaxoSmithKline, London, UK; 6. GlaxoSmithKline, Waltham, USA; 7. Sanofi, North York, Canada; 8. Roche, Basel, Switzerland展开收起
129
天
Japanese Patient Enrollment in Multi-regional Clinical Trials for New Drug Applications in Japan: Current Status and Related Factors
作者
Ito Furukawa; Mamoru Narukawa展开收起
作者单位
1. Department of Clinical Medicine (Pharmaceutical Medicine), Graduate School of Pharmaceutical Sciences, Kitasato University, Minato‑ku, Japan; 2. Sanofi Specialty Care Medical, Tokyo, Japan展开收起
166
天
Investigator-Initiated Trials as a Clinical Development Approach for Orphan Drugs Compared with Industry-Sponsored Trials in Japan
作者
Shingo Yamaguchi; Eiji Nakatani; Ryuta Asada展开收起
作者单位
1. Department of Medical Research and Development Strategy, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan; 2. Laboratory of Biostatistics, NHO Nagoya Medical Center, Nagoya, Japan展开收起
213
天
74
天
Accelerated Registration of a New Anti-infective Combination in ASEAN Markets: Experience, Insights and Learnings on the ASEAN Joint Assessment (ASEAN JA)
作者
Paul Marvin Quizon; Patriz Miga Lintag-Raymundo; Wan Lee Chow; Serene Huang; Thanh Tu Nguyen; R. Iin Nurhayati; Wipada Rodtanaporn; Tse Siang Kang展开收起
作者单位
1. Pfizer, Inc, Makati City, Philippines; 2. Pfizer (Malaysia) Sdn. Bhd, Kuala Lumpur, Malaysia; 3. Pfizer Pte. Ltd, Singapore, Singapore; 4. Pfizer (Vietnam) Ltd. Co, Hanoi, Vietnam; 5. PT Pfizer Indonesia, Jakarta, Indonesia; 6. Pfizer (Thailand) Ltd, Bangkok, Thailand展开收起
FAQ
Therapeutic Innovation & Regulatory Science审稿要多久?
截至2026-11-19,CrushSCI 收录了 Therapeutic Innovation & Regulatory Science 的 21 篇完整审稿记录。最快一篇从收稿到录用用了 44 天(Identifying and Deploying Benchmarks for Clinical Research at Sites,2026-02-04 收稿,2026-03-20 录用),最慢一篇用了 303 天;平均 159.5 天,中位数 156 天。
Expert Matching · Case Demo
把投稿要求,转成可验证的期刊方案
说清专业、时限和作者背景,CrushSCI 结合真实审稿样本,给出拟题方向、期刊初筛与周期判断。
